An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ianalumab in Patients With Sjögren's Syndrome
Latest Information Update: 16 Aug 2024
At a glance
- Drugs Ianalumab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 Feb 2024 Planned End Date changed from 12 Sep 2026 to 28 Jun 2026.
- 07 Feb 2024 Planned primary completion date changed from 11 Sep 2026 to 26 Jun 2026.
- 26 Jan 2024 Status changed from recruiting to active, no longer recruiting.